DK1332209T3 - Samlinger af repeatproteiner indeholdende repeatmoduler - Google Patents

Samlinger af repeatproteiner indeholdende repeatmoduler

Info

Publication number
DK1332209T3
DK1332209T3 DK01984591.6T DK01984591T DK1332209T3 DK 1332209 T3 DK1332209 T3 DK 1332209T3 DK 01984591 T DK01984591 T DK 01984591T DK 1332209 T3 DK1332209 T3 DK 1332209T3
Authority
DK
Denmark
Prior art keywords
repeat
collections
modules
proteins containing
repeat proteins
Prior art date
Application number
DK01984591.6T
Other languages
English (en)
Inventor
Michael Tobias Stumpp
Patrick Forrer
Hans Kaspar Binz
Andreas Plueckthun
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of DK1332209T3 publication Critical patent/DK1332209T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01984591.6T 2000-09-08 2001-09-10 Samlinger af repeatproteiner indeholdende repeatmoduler DK1332209T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00119670 2000-09-08
PCT/EP2001/010454 WO2002020565A2 (en) 2000-09-08 2001-09-10 Collections of repeat proteins comprising repeat modules

Publications (1)

Publication Number Publication Date
DK1332209T3 true DK1332209T3 (da) 2010-03-29

Family

ID=8169793

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01984591.6T DK1332209T3 (da) 2000-09-08 2001-09-10 Samlinger af repeatproteiner indeholdende repeatmoduler

Country Status (10)

Country Link
US (4) US7417130B2 (da)
EP (2) EP2149604A1 (da)
JP (3) JP5291279B2 (da)
AT (1) ATE448301T1 (da)
AU (1) AU2002218166A1 (da)
CA (1) CA2421447C (da)
DE (1) DE60140474D1 (da)
DK (1) DK1332209T3 (da)
ES (1) ES2335861T3 (da)
WO (1) WO2002020565A2 (da)

Families Citing this family (379)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20060051861A1 (en) * 2004-09-07 2006-03-09 Clonex Development, Inc. Cell lines for use in increasing protein yield from a cell culture
WO2006129828A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Target substance capturing molecule
DK1963369T3 (da) 2005-11-28 2013-06-03 Zymogenetics Inc Il-21-antagonister
AU2013201171B2 (en) * 2006-02-13 2016-01-21 Monsanto Technology Llc Plant chimeric binding polypeptides for universal molecular recognition
AU2015203464B2 (en) * 2006-02-13 2017-08-10 Monsanto Technology Llc Plant chimeric binding polypeptides for universal molecular recognition
AR059448A1 (es) * 2006-02-13 2008-04-09 Divergence Inc Polipeptidos quimericos vegetales de union para el reconocimiento molecular universal
EP1996612A4 (en) 2006-03-03 2010-10-20 Univ Kingston COMPOSITIONS FOR THE TREATMENT OF CANCER
DK2013236T3 (da) 2006-04-28 2015-09-21 Delenex Therapeutics Ag Antistoffer, der binder til det ekstracellulære domæne af receptortyrosinkinasen alk
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
HUE033630T2 (en) 2006-10-02 2017-12-28 Squibb & Sons Llc CXCR4 binding human antibodies and their use
JP5207222B2 (ja) * 2006-11-17 2013-06-12 独立行政法人農業生物資源研究所 ロイシンリッチリピート（ｌｒｒ）配列等反復配列を利用したタンパク質の作製方法
US8470332B2 (en) 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
ES2678060T3 (es) 2006-12-01 2018-08-08 E. R. Squibb & Sons, L.L.C. Anticuerpos, en particular, anticuerpos humanos, que se unen a CD22 y usos de los mismos
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
CA2682350A1 (en) * 2007-04-11 2008-10-23 The Jackson Laboratory Diagnosis and treatment of diseases caused by misfolded proteins
CA2687395C (en) 2007-05-03 2017-07-11 Medizinische Universitat Innsbruck Complement factor h-derived short consensus repeat-antibody constructs
CN101801407B (zh) 2007-06-05 2013-12-18 耶鲁大学 受体酪氨酸激酶抑制剂及其使用方法
CA2689941C (en) 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
DK2164961T3 (da) 2007-06-25 2015-03-02 Esbatech Alcon Biomed Res Unit Sekvensbaseret fremposition og optimering af enkelt-kæde-antistoffer
JP2010539915A (ja) * 2007-09-24 2010-12-24 ユニバーシティ・オブ・チューリッヒ 設計されたアルマジロリピートタンパク質
EP2222709B1 (en) 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
WO2010055366A2 (en) 2007-12-07 2010-05-20 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
US20100317599A1 (en) * 2008-02-13 2010-12-16 Alrik Pieter Los Process for the production of a peptide
CN102007145A (zh) 2008-02-14 2011-04-06 百时美施贵宝公司 基于结合egfr的工程化蛋白质的靶向治疗剂
EP2103936A1 (en) * 2008-03-19 2009-09-23 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat module and methods of their design and use
US20110262964A1 (en) * 2008-03-19 2011-10-27 Hugues Bedouelle Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
KR20220162801A (ko) 2008-04-11 2022-12-08 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
PE20091882A1 (es) 2008-05-06 2009-12-24 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
EP3629022A1 (en) 2008-07-25 2020-04-01 Richard W. Wagner Protein screening methods
EP2323695B1 (en) 2008-08-19 2018-12-05 Nektar Therapeutics Complexes of small-interfering nucleic acids
CA2742241C (en) 2008-11-03 2019-12-10 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
WO2010084408A2 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
EP3181583A1 (en) 2009-02-24 2017-06-21 ESBATech, an Alcon Biomedical Research Unit LLC Methods for identifying immunobinders of antigens
CA2753263A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
CA2753332A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｃａｄｍ１に特異的な完全ヒト抗体
KR101736076B1 (ko) 2009-04-20 2017-05-16 옥스포드 바이오테라퓨틱스 리미티드 카드헤린-１７에 특이적인 항체
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
SG177763A1 (en) 2009-07-28 2012-03-29 Hoffmann La Roche Non-invasive in vivo optical imaging method
WO2011047083A1 (en) 2009-10-13 2011-04-21 Oxford Biotherapeutics Ltd. Antibodies against epha10
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011054893A2 (en) 2009-11-05 2011-05-12 Novartis Ag Biomarkers predictive of progression of fibrosis
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
KR20130028055A (ko) 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
WO2011098449A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN107098958B (zh) 2010-03-26 2021-11-05 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
EP2563380B1 (en) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
JP6294074B2 (ja) 2010-04-27 2018-03-14 エータイアー ファーマ， インコーポレイテッド イソロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248489B2 (en) 2010-04-28 2016-10-06 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl tRNA synthetases
JP5991963B2 (ja) 2010-04-29 2016-09-14 エータイアー ファーマ， インコーポレイテッド バリルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CN103096912A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008841B2 (ja) 2010-05-03 2016-10-19 エータイアー ファーマ， インコーポレイテッド メチオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2566515B1 (en) 2010-05-03 2017-08-02 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CA2798139C (en) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
WO2011138462A1 (en) 2010-05-07 2011-11-10 F. Hoffmann-La Roche Ag Diagnostic method for the detection of cells ex vivo
ES2816898T3 (es) 2010-05-13 2021-04-06 Sarepta Therapeutics Inc Compuestos que modulan la actividad de señalización de las interleucinas 17 y 23
WO2011143482A2 (en) 2010-05-14 2011-11-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CA2800375C (en) 2010-05-27 2021-03-09 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
EP2593125B1 (en) 2010-07-12 2017-11-01 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
SG188666A1 (en) 2010-09-30 2013-05-31 Agency Science Tech & Res Methods and reagents for detection and treatment of esophageal metaplasia
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
PT2643352T (pt) 2010-11-23 2018-08-01 Glaxo Group Ltd Proteínas de ligação a antigénio para a oncostatina m (osm)
WO2012069557A1 (en) 2010-11-24 2012-05-31 Glaxo Group Limited Multispecific antigen binding proteins targeting hgf
KR20140032356A (ko) 2010-11-26 2014-03-14 몰리큘라 파트너스 아게 설계된 안키린 반복 단백질에 대한 개선된 n-말단 캡핑 모듈
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP6043629B2 (ja) 2011-01-07 2016-12-14 中外製薬株式会社 抗体の物性を改善させる方法
US9499592B2 (en) * 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
EP3666289A1 (en) 2011-02-15 2020-06-17 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
RU2016147206A (ru) 2011-04-15 2018-10-19 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
BR112013027766A2 (pt) * 2011-04-29 2016-11-29 Janssen Biotech Inc proteinas de repetição de ligação de il4/il13 e usos
HRP20211869T1 (hr) 2011-05-06 2022-03-04 Zoetis Services Llc Protutijela protiv faktora rasta živca i postupci za njihovu proizvodnju i uporabu
KR20170070272A (ko) 2011-05-06 2017-06-21 넥스베트 오스트레일리아 피티와이 리미티드 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
KR101833465B1 (ko) 2011-05-06 2018-02-28 넥스베트 오스트레일리아 피티와이 리미티드 항신경 성장 인자 항체 및 그의 제조방법과 이용방법
LT3415531T (lt) 2011-05-27 2023-09-25 Glaxo Group Limited Bcma (cd269/tnfrsf17) – surišantys baltymai
EP2717898B1 (en) 2011-06-10 2018-12-19 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
JP6209159B2 (ja) 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
PE20140756A1 (es) 2011-06-28 2014-07-04 Oxford Biotherapeutics Ltd Anticuerpos que se unen a bst1
LT2726094T (lt) 2011-06-28 2017-02-10 Oxford Biotherapeutics Ltd Gydymo ir diagnozavimo objektas
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20140335089A1 (en) 2011-09-30 2014-11-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN110655578A (zh) 2011-09-30 2020-01-07 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
RU2732151C2 (ru) 2011-09-30 2020-09-11 Чугаи Сейяку Кабусики Кайся Библиотека зависимых от концентрации ионов связывающих молекул
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN
EP2771351B1 (en) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1 epitopes and methods for using same
WO2013074840A1 (en) 2011-11-15 2013-05-23 Allergan, Inc. Treatment of dry age related macular degeneration
WO2013081143A1 (ja) 2011-11-30 2013-06-06 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
EP2612916A1 (en) 2012-01-09 2013-07-10 Universität Zürich Cellular high throughput encapsulation for screening or selection
CA2860579A1 (en) 2012-01-10 2013-07-18 Biogen Idec Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
RS60583B1 (sr) 2012-02-13 2020-08-31 Agency Science Tech & Res Ljudska monoklonalna antitela koja vrše neutralizaciju il-ss
EP2814514B1 (en) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
US20150037251A1 (en) 2012-02-17 2015-02-05 Universitat Bern Mammalian homologues of flower, their use in cancer diagnostics, prevention and treatment
CN107266564A (zh) 2012-02-24 2017-10-20 中外制药株式会社 经由FcγIIB促进抗原消除的抗原结合分子
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
ES2753135T3 (es) 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
CA2874721A1 (en) 2012-05-30 2013-12-05 Tomoyuki Igawa Target tissue-specific antigen-binding molecule
DK2857419T3 (da) 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til eliminering af aggregerede antigener
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
SG11201408196RA (en) * 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
AR091774A1 (es) 2012-07-16 2015-02-25 Dow Agrosciences Llc Proceso para el diseño de las secuencias de adn repetidas, largas, divergentes de codones optimizados
EP2692731A1 (en) * 2012-07-31 2014-02-05 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
BR112015001955A2 (pt) 2012-08-24 2017-11-07 Chugai Pharmaceutical Co Ltd variante de região fc específica de fcgamariib
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
RU2683933C2 (ru) 2012-09-28 2019-04-03 Чугаи Сейяку Кабусики Кайся Способ для оценки реакции коагуляции крови
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
AU2013331763B2 (en) 2012-10-15 2018-02-15 Universitat Zurich Bispecific HER2 ligands for cancer therapy
AU2013343667A1 (en) 2012-11-08 2015-04-02 F. Hoffmann-La Roche Ag HER3 antigen binding proteins binding to the beta-hairpin of HER3
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
ES2876009T3 (es) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Polipéptido heterodimerizado
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP3444278A1 (en) 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
DK2962100T3 (da) 2013-02-28 2021-11-01 Caprion Proteomics Inc Tuberkulosebiomarkører og anvendelser deraf
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
EP3004152B1 (en) 2013-05-31 2020-09-30 Molecular Partners AG Designed ankyrin repeat proteins binding to hepatocyte growth factor
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
WO2015051199A2 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
US20150126458A1 (en) 2013-11-05 2015-05-07 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
KR20220142539A (ko) 2013-12-04 2022-10-21 추가이 세이야쿠 가부시키가이샤 화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리
JP6553618B2 (ja) 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法
DK3087098T3 (da) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista-antistoffer og -fragmenter
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR20150092638A (ko) 2014-02-05 2015-08-13 삼성전자주식회사 p15 단백질 변이체 및 이를 포함하는 암의 예방 또는 치료용 조성물
KR20150092637A (ko) 2014-02-05 2015-08-13 삼성전자주식회사 p16 단백질 변이체 및 이를 포함하는 암의 예방 또는 치료용 조성물
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
CA2951885C (en) 2014-06-11 2023-07-04 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
CR20170111A (es) 2014-09-03 2017-05-23 Immunogen Inc Derivados de benzodiazepina citotóxicos
JP6863888B2 (ja) 2014-10-01 2021-04-21 メディミューン，エルエルシー ポリペプチドをコンジュゲートさせる方法
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
EP3489256B1 (en) 2014-11-14 2021-03-17 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
JP6743022B2 (ja) 2014-12-24 2020-08-19 ネクシミューン インコーポレイテッド 免疫療法のためのナノ粒子組成物及び方法
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
EP4272838A3 (en) 2015-04-02 2024-01-10 Molecular Partners AG Designed ankyrin repeat domains with binding specificity for serum albumin
BR112017016952A2 (pt) 2015-04-17 2018-04-03 F. Hoffmann-La Roche Ag terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
BR112017025995A2 (pt) 2015-06-04 2018-08-14 Ospedale San Raffaele S.R.L. inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
CA2988011C (en) 2015-06-04 2021-03-23 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
KR101713944B1 (ko) * 2015-06-19 2017-03-09 한국과학기술원 신규한 혈관내피세포 성장인자와 결합할 수 있는 폴리펩타이드 및 이의 용도
US11009509B2 (en) 2015-06-24 2021-05-18 Janssen Pharmaceutica Nv Anti-VISTA antibodies and fragments
PT3331910T (pt) 2015-08-03 2020-03-24 Engmab Sarl Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
KR20230079500A (ko) 2015-09-18 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8에 결합하는 항체 및 그의 사용
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356411B1 (en) 2015-10-02 2021-06-30 F. Hoffmann-La Roche AG Bispecific antibodies specific for pd1 and tim3
MA43017A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
EP3359568B1 (en) 2015-10-07 2022-03-09 F. Hoffmann-La Roche AG Bispecific antibodies with tetravalency for a costimulatory tnf receptor
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
MX2018006194A (es) 2015-11-19 2018-12-06 Asclepix Therapeutics Llc Peptidos con propiedades antiangiogenicas, antilinfangiogenicas y antiedemicas y formulaciones de nanoparticulas.
EP3978010A1 (en) 2015-12-02 2022-04-06 Fred Hutchinson Cancer Research Center Circular tandem repeat proteins
CN117024599A (zh) 2016-02-05 2023-11-10 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
TW202216201A (zh) 2016-02-12 2022-05-01 比利時商楊森製藥公司 抗vista抗體及片段、其用途及鑑定其之方法
EP3426278B1 (en) 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
CN117562992A (zh) 2016-04-15 2024-02-20 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
CN109071652B (zh) 2016-05-11 2022-09-23 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
WO2018011405A1 (en) 2016-07-15 2018-01-18 Universität Zürich Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
BR112019005587A2 (pt) 2016-09-22 2019-06-11 Molecular Partners Ag proteínas de ligação recombinantes e sua utilização
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
CN110177563A (zh) 2016-10-04 2019-08-27 阿斯克雷佩西治疗公司 用于激活tie2信号传导的化合物和方法
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
US11697680B2 (en) 2016-11-21 2023-07-11 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates
BR112019008727A2 (pt) 2016-11-28 2019-07-16 Chugai Pharmaceutical Co Ltd domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte
KR102533814B1 (ko) 2016-11-28 2023-05-19 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
TWI829628B (zh) 2016-12-19 2024-01-21 瑞士商赫孚孟拉羅股份公司 與靶向4-1bb (cd137)促效劑併用之組合療法
AU2017384126A1 (en) 2016-12-20 2019-05-02 F. Hoffmann-La Roche Ag Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
RU2019123613A (ru) 2017-01-03 2021-02-05 Ф. Хоффманн-Ля Рош Аг Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3576765A4 (en) 2017-02-06 2020-12-02 Orionis Biosciences, Inc. TARGETED ENGINEERING INTERFERON AND USES OF IT
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
RU2765098C2 (ru) 2017-02-28 2022-01-25 Иммуноджен, Инк. Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
JP7196094B2 (ja) 2017-03-29 2022-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
KR20190133230A (ko) 2017-03-31 2019-12-02 고리츠다이가쿠호징 나라켕리츠 이카다이가쿠 혈액 응고 제viii 인자의 기능을 대체하는 다중 특이성 항원 결합 분자를 함유하는, 혈액 응고 제ix 인자 이상증의 예방 및/또는 치료에 이용되는 의약 조성물
AU2018247796A1 (en) 2017-04-04 2019-08-29 F. Hoffmann-La Roche Ag Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
CN110506059B (zh) 2017-04-05 2023-01-17 豪夫迈·罗氏有限公司 特异性结合pd1和lag3的双特异性抗体
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
WO2019028427A1 (en) 2017-08-03 2019-02-07 Asclepix Therapeutics, Llc. METHODS OF IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE TIE2 RECEPTOR
EA202090641A1 (ru) 2017-09-29 2020-08-07 Чугаи Сейяку Кабусики Кайся Мультиспецифическая антиген-связывающая молекула, обладающая замещающей функциональной активностью кофактора коагулирующего фактора крови viii, и фармацевтическая композиция, содержащая указанную молекулу в качестве активного ингредиента
US11466073B2 (en) 2017-10-18 2022-10-11 Csl Limited Human serum albumin variants and uses thereof
CN111182944B (zh) 2017-11-01 2022-11-22 豪夫迈·罗氏有限公司 双特异性2+1 Contorsbody
AU2018359506A1 (en) 2017-11-01 2020-04-23 F. Hoffmann-La Roche Ag Combination therapy with targeted OX40 agonists
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
WO2019107380A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
US20210206845A1 (en) 2017-11-28 2021-07-08 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
KR20200093562A (ko) 2017-11-29 2020-08-05 씨에스엘 리미티드 허혈-재관류 손상을 치료 또는 예방하는 방법
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
JP2021508714A (ja) 2017-12-28 2021-03-11 イミュノジェン・インコーポレーテッド ベンゾジアゼピン誘導体
MX2020006956A (es) 2018-01-05 2020-11-06 Ac Immune Sa Moleculas de union a tdp-43 mal plegadas.
JP2021511782A (ja) 2018-01-31 2021-05-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 安定化された免疫グロブリンドメイン
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
AU2019215440A1 (en) 2018-02-05 2020-08-27 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
JP7350756B2 (ja) 2018-02-14 2023-09-26 アバ セラピューティクス アーゲー 抗ヒトｐｄ－ｌ２抗体
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
CA3090232A1 (en) 2018-03-13 2019-09-19 F. Hoffmann-La Roche Ag Combination therapy with targeted 4-1bb (cd137) agonists
EP3765489A1 (en) 2018-03-13 2021-01-20 F. Hoffmann-La Roche AG Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
WO2019180243A1 (en) 2018-03-22 2019-09-26 Charité-Universitätsmedizin Berlin Crispr associated protein reactive t cell immunity
PE20210652A1 (es) 2018-04-13 2021-03-26 Hoffmann La Roche Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
JP2021523733A (ja) * 2018-04-18 2021-09-09 アルティウス インスティテュート フォー バイオメディカル サイエンスィズ 動物病原体由来ポリペプチドおよびその遺伝子工学的利用
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
EP3807401A1 (en) 2018-06-15 2021-04-21 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
EP3812399A4 (en) 2018-06-20 2022-03-23 Chugai Seiyaku Kabushiki Kaisha METHOD FOR ACTIVATING THE IMMUNE RESPONSE OF A TARGET CELL AND ASSOCIATED COMPOSITION
CN112424228A (zh) 2018-07-04 2021-02-26 豪夫迈·罗氏有限公司 新型双特异性激动性4-1bb抗原结合分子
BR112021002037A2 (pt) 2018-08-10 2021-05-04 Chugai Seiyaku Kabushiki Kaisha molécula de ligação de antígeno anti-cd137 e uso da mesma
WO2020070035A1 (en) 2018-10-01 2020-04-09 F. Hoffmann-La Roche Ag Bispecific antigen binding molecules with trivalent binding to cd40
UA126188C2 (uk) 2018-10-01 2022-08-25 Ф. Хоффманн-Ля Рош Аг Біспецифічна антигензв'язувальна молекула, яка містить домен зв'язування з fap та домен зв'язування з сd40
EP3632929A1 (en) 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antibodies and uses thereof
BR112021005670A2 (pt) 2018-10-08 2021-06-22 Universität Zürich polipeptídeos tetraméricos de ligação a her2
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
WO2020104627A1 (en) 2018-11-21 2020-05-28 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
AR117728A1 (es) 2018-12-21 2021-08-25 Hoffmann La Roche Moléculas superagonistas de unión al antígeno cd28 con diana tumoral
WO2020127618A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
WO2020144378A1 (en) 2019-01-11 2020-07-16 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
BR112021016056A2 (pt) 2019-02-15 2021-12-14 Integral Molecular Inc Anticorpos de claudina 6 e usos dos mesmos
EP3924379A4 (en) 2019-02-15 2022-12-21 Integral Molecular, Inc. COMMON LIGHT CHAIN ANTIBODIES AND THEIR USES
JPWO2020175502A1 (ja) 2019-02-27 2021-12-23 国立大学法人 東京医科歯科大学 抗原結合タンパク質と蛍光タンパク質または蛍光標識されるタグタンパク質との融合タンパク質
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
US20220154174A1 (en) 2019-03-08 2022-05-19 Oxford Genetics Limited Method of Selecting for Antibodies
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
CN113613676A (zh) 2019-03-19 2021-11-05 中外制药株式会社 包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
KR20220022112A (ko) 2019-03-21 2022-02-24 이뮤노젠 아이엔씨 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법
TW202102506A (zh) 2019-03-29 2021-01-16 美商伊繆諾金公司 苯二氮平衍生物
CA3134705A1 (en) 2019-04-02 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene
US20220178926A1 (en) 2019-04-10 2022-06-09 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
EP3952996A1 (en) 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising lipocalin muteins
EP3956027A1 (en) 2019-04-18 2022-02-23 AC Immune SA Novel molecules for therapy and diagnosis
PT3958977T (pt) 2019-04-26 2023-12-15 Immunogen Inc Derivados de camptotecina
AU2020279224A1 (en) 2019-05-21 2021-12-16 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
SG11202111281TA (en) 2019-05-21 2021-12-30 Novartis Ag Cd19 binding molecules and uses thereof
US20230071196A1 (en) 2019-05-21 2023-03-09 Novartis Ag Variant cd58 domains and uses thereof
AU2020278907A1 (en) 2019-05-23 2022-01-20 Ac Immune Sa Anti-TDP-43 binding molecules and uses thereof
KR20220016942A (ko) 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 재조합 fap 결합 단백질 및 이의 용도
BR112021024237A2 (pt) 2019-06-04 2022-04-19 Molecular Partners Ag Domínio de repetição de anquirina projetado com estabilidade aprimorada
US20220298212A1 (en) 2019-06-04 2022-09-22 Molecular Partners Ag Recombinant 4-1bb binding proteins and their use
CN114206943A (zh) 2019-06-04 2022-03-18 分子伴侣公司 多特异性蛋白质
MX2021014433A (es) 2019-06-05 2022-03-11 Chugai Pharmaceutical Co Ltd Molecula de union a sitio de escision de anticuerpo.
US20220315909A1 (en) 2019-06-05 2022-10-06 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
EP3982369A4 (en) 2019-06-07 2023-06-14 Chugai Seiyaku Kabushiki Kaisha INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING PROCESS, PROGRAM AND METHOD FOR PRODUCTION OF AN ANTIGEN-BINDING MOLECULE OR PROTEIN
CN113993548A (zh) 2019-06-18 2022-01-28 马克思—普朗克科学促进协会公司 标记物和/或载体与靶分子例如带His-标签的蛋白质通过金属配合物试剂的位点特异性动力学惰性缀合
JP2022538075A (ja) 2019-06-26 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体結合ｃｅａ及び４－１ｂｂｌの融合
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
WO2021044050A1 (en) 2019-09-05 2021-03-11 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
CA3154526A1 (en) 2019-11-15 2021-05-20 Enthera S.R.L. Tmem219 antibodies and therapeutic uses thereof
WO2021099484A1 (en) 2019-11-20 2021-05-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Archaeal peptide recombinase – a novel peptide ligating enzyme
AR120512A1 (es) 2019-11-20 2022-02-16 Chugai Pharmaceutical Co Ltd Formulaciones que contienen anticuerpos
JP2023503105A (ja) 2019-11-21 2023-01-26 エンテラ・エッセ・エッレ・エッレ Ｉｇｆｂｐ３抗体及びその治療的使用
WO2021104511A1 (zh) 2019-11-29 2021-06-03 苏州诺沃泰医药科技有限公司 Cart细胞在制备治疗癌症的药物中的应用
CN115003689A (zh) 2019-12-11 2022-09-02 分子合作伙伴股份公司 具有改变的表面残基的经设计的锚蛋白重复结构域
JP2023506763A (ja) 2019-12-11 2023-02-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えペプチド－ｍｈｃ複合体結合タンパク質並びにそれらの生成及び使用
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
EP4132578A1 (en) 2020-04-06 2023-02-15 Universität Zürich Artc1 ligands for cancer treatment
JP2023525518A (ja) 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途
AU2021271131A1 (en) 2020-05-14 2022-12-15 Molecular Partners Ag Recombinant CD40 binding proteins and their use
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
TW202214303A (zh) 2020-05-19 2022-04-16 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之結合分子
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
US20220017637A1 (en) 2020-06-23 2022-01-20 Hoffmann-La Roche Inc. Agonistic cd28 antigen binding molecules targeting her2
EP4172203A1 (en) 2020-06-25 2023-05-03 F. Hoffmann-La Roche AG Anti-cd3/anti-cd28 bispecific antigen binding molecules
KR20230048059A (ko) 2020-07-31 2023-04-10 추가이 세이야쿠 가부시키가이샤 키메라 수용체를 발현하는 세포를 포함하는 의약 조성물
TW202221008A (zh) 2020-08-07 2022-06-01 瑞士商赫孚孟拉羅股份公司 製備蛋白質組成物之方法
EP4196162A1 (en) 2020-08-14 2023-06-21 AC Immune SA Humanized anti-tdp-43 binding molecules and uses thereof
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
EP4199964A1 (en) 2020-08-18 2023-06-28 Universität Zürich A cd25-biased anti-il-2 antibody
WO2022043517A2 (en) 2020-08-27 2022-03-03 Cureab Gmbh Anti-golph2 antibodies for macrophage and dendritic cell differentiation
EP4209227A4 (en) 2020-09-01 2024-05-29 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF PRURITUS IN DIALYSIS CONTAINING AN IL-31 ANTAGONIST AS ACTIVE INGREDIENT
IL302087A (en) 2020-10-15 2023-06-01 Genentech Inc History links versican hyaluronic acid (VG1) to long-term delivery of treatments
EP4229082A1 (en) 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
CN112230587B (zh) * 2020-10-29 2021-08-10 中国民用航空总局第二研究所 一种仪表着陆系统同频异呼运行监测系统及方法
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
EP4244254A1 (en) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Combination therapy with fap-targeted cd40 agonists
US20240018265A1 (en) 2020-12-11 2024-01-18 Friedrich Miescher Institute For Biomedical Research Hdac6 binding proteins and their anti-viral use
WO2022130300A1 (en) 2020-12-16 2022-06-23 Molecular Partners Ag Novel slow-release prodrugs
CA3202296A1 (en) 2020-12-16 2022-06-23 Sebastian Grimm Recombinant cd3 binding proteins and their use
WO2022148732A1 (en) 2021-01-06 2022-07-14 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
CA3209479A1 (en) 2021-02-03 2022-08-11 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022171831A1 (en) 2021-02-11 2022-08-18 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
BR112023018293A2 (pt) 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
WO2022190018A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
WO2022190008A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Protease cleavable prodrugs
CA3211248A1 (en) 2021-03-09 2022-09-15 Nina RESCHKE Novel darpin based cd33 engagers
WO2022219185A1 (en) 2021-04-16 2022-10-20 Athebio Ag N-terminal capping modules of ankyrin repeat domains
WO2022244838A1 (ja) 2021-05-19 2022-11-24 中外製薬株式会社 分子のｉｎ ｖｉｖｏ薬物動態を予測する方法
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
AU2022322029A1 (en) 2021-08-05 2024-02-15 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
BR112024002198A2 (pt) 2021-08-05 2024-04-30 Immunos Therapeutics Ag Composições farmacêuticas compreendendo proteínas de fusão do hla
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023021050A1 (en) 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
EP4137508A1 (en) 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
AU2022390134A1 (en) 2021-11-16 2024-05-16 Ac Immune Sa Novel molecules for therapy and diagnosis
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
TW202340248A (zh) 2021-12-20 2023-10-16 瑞士商赫孚孟拉羅股份公司 促效性ｌｔｂｒ抗體及包含其之雙特異性抗體
WO2023117987A1 (en) 2021-12-21 2023-06-29 Universität Zürich Adenoviral vectors
TW202342519A (zh) 2022-02-16 2023-11-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2023186756A1 (en) 2022-03-28 2023-10-05 F. Hoffmann-La Roche Ag Interferon gamma variants and antigen binding molecules comprising these
WO2023195515A1 (ja) * 2022-04-06 2023-10-12 独立行政法人国立高等専門学校機構 反復塩基配列および反復回数が互いに異なる核酸からなる混合集団の構築方法
WO2023194565A1 (en) 2022-04-08 2023-10-12 Ac Immune Sa Anti-tdp-43 binding molecules
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
US20240132546A1 (en) 2022-07-31 2024-04-25 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2023194628A2 (en) 2022-08-16 2023-10-12 Athebio Ag Variants of ankyrin repeat domains
WO2024037743A1 (en) 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
WO2024047114A1 (en) 2022-08-31 2024-03-07 Universität Zürich Adenoviral-based in situ delivery of bispecific t cell engagers
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
WO2024077118A2 (en) 2022-10-06 2024-04-11 Bicara Therapeutics Inc. Multispecific proteins and related methods
WO2024074706A1 (en) 2022-10-07 2024-04-11 Universität Zürich Paracrine adenoviral delivery of biomolecules
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612340B2 (en) * 1986-11-04 1991-07-11 Protein Polymers Technologies, Inc. Construction of synthetic dna and its use in large polypeptide synthesis
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
KR0185192B1 (ko) 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
DK0656950T3 (da) 1992-08-21 1999-07-19 Biogen Inc TAT-afledte transportpolypeptider
JP4118327B2 (ja) 1994-08-20 2008-07-16 ゲンダック・リミテッド Ｄｎａ認識のための結合タンパク質におけるまたはそれに関連する改良
DE19631106A1 (de) 1996-08-01 1998-02-05 Heinz Peter Brandstetter Statorplatte oder Statorelement
US5932440A (en) * 1996-08-16 1999-08-03 Life Technologies, Inc. Mammalian ribonuclease inhibitors and use thereof
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
CA2289691C (en) 1997-04-23 2008-01-15 Andreas Pluckthun Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
US5827692A (en) * 1997-04-24 1998-10-27 Heska Corporation Dirofilaria and Brugia ankyrin proteins, nucleic acid molecules, and uses thereof
WO1999003494A1 (en) * 1997-07-18 1999-01-28 Yale University STRUCTURE OF THE ANKYRIN BINDING DOMAIN OF A ALPHA-Na,K-ATPase
IL143238A0 (en) 1998-12-02 2002-04-21 Phylos Inc Dna-protein fusions and uses thereof
DK1137941T4 (da) * 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
US20020042094A1 (en) * 1999-12-15 2002-04-11 Venezia Domenick R. RING finger protein zapop2
AU2001251695A1 (en) * 2000-02-17 2001-08-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
US20020035739A1 (en) 2000-05-05 2002-03-21 Michael Lassner Evolution of plant disease response plant pathways to enable the development of based biological sensors and to develop novel disease resistance strategies
WO2002002739A2 (en) * 2000-06-29 2002-01-10 University Of Florida Ubiquitin ligase

Also Published As

Publication number Publication date
CA2421447C (en) 2012-05-08
JP2013179942A (ja) 2013-09-12
US9006389B2 (en) 2015-04-14
AU2002218166A1 (en) 2002-03-22
WO2002020565A2 (en) 2002-03-14
US9657287B2 (en) 2017-05-23
DE60140474D1 (de) 2009-12-24
ES2335861T3 (es) 2010-04-06
US20040132028A1 (en) 2004-07-08
WO2002020565A3 (en) 2002-11-07
ATE448301T1 (de) 2009-11-15
EP2149604A1 (en) 2010-02-03
US8110653B2 (en) 2012-02-07
US20090082274A1 (en) 2009-03-26
US20150275201A1 (en) 2015-10-01
EP1332209A2 (en) 2003-08-06
JP2016053031A (ja) 2016-04-14
JP5291279B2 (ja) 2013-09-18
EP1332209B1 (en) 2009-11-11
CA2421447A1 (en) 2002-03-14
US20120142611A1 (en) 2012-06-07
US7417130B2 (en) 2008-08-26
JP2004508033A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
DK1332209T3 (da) Samlinger af repeatproteiner indeholdende repeatmoduler
DE60310731D1 (de) Neue, von noraporphin abgeleitete moleküle
DE602004009764D1 (de) Pha-klebstoffe
CY1112101T1 (el) Νευροτροφικοι παραγοντες
DK3184545T3 (da) Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein
DE60223451D1 (de) System zur Quittierung von Datenpaketen
NO20042159L (no) Cellokulturprosess
SE9803838D0 (sv) A chromatography method and a column material useful in said method
DE60112276D1 (de) Elektrophoretische trennung von verbindungen
CY1111278T1 (el) Συστημα ασφαλειας
DE60300734D1 (de) Anordnungen zur Vorbehandlung von Proben
ATE512228T1 (de) Induzierbare expressionssysteme
ATE453648T1 (de) Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
ATE446314T1 (de) Methode zur reinigung von fsh
DK1680430T3 (da) Fremgangsmåder til fremstilling af form I af (S)-(+)-Clopidogrel-bisulfat
DE60143490D1 (de) Von oligoolefinen mit funktionellen endgruppen abgeleitete funktionelle substanzen
ATE506351T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- oxo-5h-dibenzoäb,füazepin-5-carboxamid
DE60213941D1 (de) Proben-Einführungssystem
DK1366195T3 (da) Fremgangsmåde til detektion af nukleinsyremolekyler
ES2133781T3 (es) Composiciones cataliticas y revestimientos realizados a partir de las mismas.
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
DE10294286D2 (de) Herstellung von trägergebundenen Molekülen
NO20041763L (no) Regulert nukleinsyreekspresjonssystem
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
DE60201084D1 (de) Herstellung von cyclischen esteroligomeren